ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

A biosimilar yielded equivalent response rates to trastuzumab at 24 weeks in a study of women with HER2-positive metastatic breast cancer.

In patients with HER2-positive breast cancer undergoing trastuzumab therapy, the use of an ACE inhibitor or beta-blocker could protect against cardiac toxicity.

Polymorphisms in the FCGR3A gene are correlated with degree of benefit from trastuzumab in women with ERBB2/HER2-positive breast cancer, according to a new analysis.

The antibody-drug conjugate trastuzumab emtansine (T-DM1) showed non-inferior—but not superior—efficacy to trastuzumab plus a taxane in women with advanced HER2-positive breast cancer.

In patients with HER2-positive breast cancer undergoing trastuzumab therapy, elevated troponin I or T before the treatment is associated with an increased risk of trastuzumab-related cardiac dysfunction.

Response to the HER2-targeted therapies lapatinib and trastuzumab are correlated with pathway-level genetic alterations, but not specific gene mutations.

Breast cancer tumors that are HER2-negative can spontaneously flip, with populations of circulating HER2-positive cells, suggesting treatment strategy.

Pages

Subscribe to HER2-Positive Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.